Artiva biotherapeutics reports second quarter 2024 financial results and recent business highlights

Strong balance sheet with successful completion of upsized $179.0 million initial public offering treatment initiated in the first patient in an investigator-initiated basket trial of allonk® exploring multiple autoimmune indications treated first patient in artiva sponsored phase 1/1b trial in patients with class iii or iv lupus nephritis (ln) and expanded trial to include patients with systemic lupus erythematosus (sle) without kidney involvement san diego, aug. 29, 2024 (globe newswire) -- artiva biotherapeutics, inc. (nasdaq: artv), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the second quarter ended june 30, 2024, and highlighted recent progress. “artiva is at an inflection point as we advance allonk® in clinical development across multiple autoimmune indications and transition to a publicly traded company,” said fred aslan, m.d.
ARTV Ratings Summary
ARTV Quant Ranking